Evaxion to present one-year clinical efficacy data from its phase 2 study on lead cancer vaccine candidate, evx-01, at the esmo congress 2024 in september

Copenhagen, denmark, aug. 08, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, is proud to announce the presentation of one-year clinical efficacy phase 2 data for its lead compound evx-01 at the european society for medical oncology (esmo) congress 2024, taking place in barcelona, spain, from september 13-17, 2024. the evx-01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma (skin cancer).
EVAX Ratings Summary
EVAX Quant Ranking